medimmune inc
-
Silicon Valley software giant Oracle Corp. announced a deal Monday to buy Micros Systems for $5.3 billion, eyeing the Columbia firm for its niche supplying technology to hotels, restaurants and retailers around the world. - Pfizer said on Monday it had abandoned its current attempt to buy AstraZeneca for nearly $118 billion — a deal watched warily by Maryland officials — as a deadline approached without a last-minute change of heart by the British drugmaker.
- Research labs closed by pharmaceutical giant Pfizer dot the country. Maryland officials don't want the state to join that list, so Pfizer's proposal to buy AstraZeneca — which employs 3,100 in the state — has prompted local angst.
- Gov. Martin O'Malley and Delaware's governor sent a joint letter to Pfizer Thursday expressing concerns about its plans to acquire pharmaceutical firm AstraZeneca, which employs thousands in both states.
- Biotechnology company MedImmune said Tuesday it has expanded a bioresearch collaboration it started with the University of System of Maryland.
- Enjoy the outdoors at Historic Ellicott City's annual Spring Celebration on Saturday, April 19, from noon to 7:30 p.m.
- A University of Maryland program that matches researchers with companies has awarded $4.1 million to 15 teams working to bring technology products to market
- Drug maker MedImmune and the University of Maryland, Baltimore, have entered into a $6 million partnership to conduct bioscience research.
- Grotech Ventures will be the first venture capital firm to invest in Maryland startup companies using $12 million in state money as part of the InvestMaryland program, state economic development officials said Wednesday.
- MedImmune leaders say the company is at a key point in developing drugs for AstraZeneca and has grown despite fears its acquisition would hurt Maryland.
- Human Genome, which uses the human DNA sequence to develop targeted drugs, was able to raise its price to $14.25 for sale to London-based GlaxoSmithKline Plc, valuing the company at $3.6 billion. In April, GlaxoSmithKline offered to buy Human Genome for $13 a share, or $2.6 billion.
- Industrial employment in Maryland and Washington, D.C., fell 2.3 percent in a year-over-year period ending in May, Manufacturers' News Inc. reported Monday.
- Maryland has hosted 1,775 clinical trials for new medicines targeting major diseases since 1999, including 369 that are still in the early stages of recruiting patients, according to a study by two pharmaceutical industry groups released Friday.
- A proposal to speed the approval of new prescription drugs has patient advocates and biotechnology firms, including many that are based in Maryland, hoping that Congress can deliver a rare dose of bipartisanship this year.
- Human Genome ultimately rebuffed a $2.6 billion offer by biopharmaceutical giant GlaxoSmithKline Plc, saying it was too low – though it has put itself on the market. Catalyst agreed to be acquired by a larger Illinois competitor for $4.4 billion.
- A Maryland plan to sell tax credits to insurance companies succeeded in raising $84 million in a novel online auction, and the revenue will be pumped into promising technology companies across the state over the next 18 months, officials said.
-
- Maryland officials are pitching the state's talent pool —corporate executives, academics and consultants that regularly deal with the federal government — as a resource for supporting existing companies and attracting new ones.
- The announcement this week that Chicago-based Exelon Corp. has struck a deal to take over Constellation came as something of a psychic blow. If the $7.9 billion deal is approved, and the parent of local utility BGE is absorbed , then Baltimore will lose its sole remaining Fortune 500 headquarters.
